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implantation.
METHODS Sixty patients (45 men (75%), 55  7 years) with a docu-
mented single vessel type A or B1 lesion, either stable or unstable
angina without biochemical signs of myocardial infarction, were
included in this single blind randomized clinical trial. Patients were
randomized to implantation of a DES or BVS (Xience Prime or
ABSORB, respectively) in a one-to-one fashion. Approximately 1
month after percutaneous coronary intervention patients underwent
H215O PET to assess (hyperemic) MBF, cold pressor test MBF, and
CFR.
RESULTS Lesions were predominantly located in the LAD (n¼36,
60%) and less frequently in the RCA (n¼14, 23%) or Cx (n¼10, 17%).
One patient refused PET perfusion at 1 month follow-up (DES arm).
MBF of the treated myocardial territory during rest, CPT, and hyper-
emia of DES was comparable with the BVS arm (0.96  0.24 vs. 1.02 
0.28 mLmin-1g-1, p¼0.38, 1.08  0.23 vs. 1.20  0.38 mLmin-1g-1,
p¼0.16, and 3.33  0.77 vs. 3.04  0.80 mLmin-1g-1, p¼0.16,
respectively). CFR of the treated territory was signiﬁcantly lower in
the BVS arm compared to DES (3.09  0.94 vs. 3.57  0.85, p<0.05). No
signiﬁcant differences in (hyperemic) MBF, CPT, and CFR were
documented in remote areas between treatment arms. Also, a trend
toward an attenuated remote CFR was observed in the BVS treatment
arm (3.03  0.86 vs. 3.48  0.96 mLmin-1g-1, p¼0.06).
CONCLUSIONS CFR is attenuated one month after implantation of a
BVS compared with a DES, although, quantitative hyperemic MBF was
not different between both treatment arms.
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BACKGROUND The safety and performance of the current Absorb
Bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa
Clara, CA) has been previously established in 101 patients enrolled in
the Cohort B of the First-in-Man ABSORB trial. At 48 months, MACE
rate in Cohort B was 10.1%, with no scaffold thrombosis (ST) reported.
ABSORB EXTEND was initiated as a global, continued access, inter-
national (outside of the US) study to expand the clinical experience
with the Absorb BVS to different geographies. Of note, investigators
were allowed to treat patients with longer coronary lesions and
smaller vessels than those in the Cohort B trial, using either longer
scaffold lengths or planned overlap with the 2.5-mm and 3.0-mm
Absorb BVS.
METHODS ABSORB EXTEND is a prospective, single-arm, open-label
clinical study that enrolled 812 subjects at 56 sites. Included were
patients with lesions  28 mm in length and reference vessel diameter
of 2.0 mm - 3.3 mm (as assessed by on-line QCA or IVUS). Treatment of
a maximum of two de novo native coronary artery lesions, each in a
different epicardial vessel, was permitted.
RESULTS Interim 24-month data in the ﬁrst 450 ABSORB EXTEND
study patients has been previously presented. Among patients
included, 33% had unstable angina, 29% prior MI and 27% diabetes
mellitus. Mean RVD and mean lesion length were 2.610.35 mm and
11.614.89 mm, respectively. In these 450 patients, hierarchical
MACE, TVF and def/prob ST rates at 2 years were 6.7%, 7.4% and 1.1%,
respectively. Long-term (36-month) follow-up data will be presented
for the ﬁrst 500 patients enrolled with the aim of providing substan-
tial data on long-term safety and performance of the Absorb BVS in a
larger population of patients, including those with planned over-
lapping and dual vessel treatment.
CONCLUSIONS Long-term outcomes in approximately 500 patients at
36 months (the largest patient cohort reported at this time point to
date) from ABSORB EXTEND will provide further insight into the
safety and performance of the Absorb BVS.
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BACKGROUND The aim of this single center observational study was
to investigate the feasibility of bioresorbable vascular scaffold (BVS)
in treatment in-stent restenosis lesions. In stent restenosis is still a
relatively common problem in daily practice. Existing solutions were
not fully effective so far. The use of drug-eluting stents (DES) is
related with increased thrombosis risk, also drug-eluting balloon has
disadvantage because the eluted-drug stays in the arterial wall only
for few weeks, which is not sufﬁcient to eliminate the risk of reste-
nosis. Bioresorbable scaffolds could be possible solution of this issue.
The BVS has a number of proposed advantages over current metallic
stent technology which could be helpful in providing short-term
vessel scaffolding and capability of prolonged drug delivery.
METHODS Between October 2013 and January 2015, 53 Patients (61
lesions) were enrolled in single arm prospective open label study in
which in stent restenosis lesions was suitable for BVS implantation.
Primary endpoints were procedural success of deployment of the BVS
at the target lesion and absence of in-hospital major adverse events
(death, Q-wave myocardial infarction, stroke or any repeat target
lesion revascularization). The mean patient age was 6412 years and
78% patients were male, 93% suffered from hypertension and 31%
from diabetes. PCI procedures were performed in 87% patients pre-
senting with stable CAD and 13% with acute coronary syndrome. Ac-
cording to the angiographic ISR pattern 45% lesions were focal and
55% were diffuse, the majority of the lesions was post DES ISR (79%).
Procedural OCT evaluation was performed in all lesions (100%) before
and post-BVS implantation. Estimate the size of the BVS was made on
the basis of the IVUS examination just after ﬁrst balloon predilatation.
Lesion pre-dilatation was mandatory and post dilatation was needed
in 92% of cases. After 6 month of BVS implantation clinical evaluation
was made, the next 6 month patients had performed control angiog-
raphy with OCT.
RESULTS Procedural success was obtained in all cases. No in-hospital
clinical events and intra-procedural or acute BVS-in-stent thrombosis
were reported. Mean BVS implanted length was 30,5 mm. A number of
1.6 stents were implanted per lesion. At a median of 6 months follow
up 2 clinically-driven TLR ( 3.8% per patient) were reported due to
recurrent ISR at the BVS-in-stent implantation site. No cardiac death,
Q-wave MI occurred at follow-up. Re-evaluation by angiography with
OCT will be obtained in next 12 months follow-up after procedure.
CONCLUSIONS The results of our study suggest that BVS is safe and
technically feasible for the treatment of ISR in patients presenting
with both stable CAD and ACS with reasonable midterm outcomes.
Moreover, follow-up revealed a very low rate of adverse events in
patients treated by BVS implantation in the context of treatment of in-
stent restenosis.
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BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and
the Pt-Cr everolimus-eluting stent with abluminal bioabsorbable
polymer (Synergy) have shown positive clinical results in trials.
However, there are important differences in the respective platforms
which could impact on clinical performance during implantation.
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consecutive patients in stable clinical condition and with lesions
amenable to be treated with the BVS stent according to predeﬁned
criteria. Patients were randomized to either treatment with BVS or
Synergy. The procedure was performed according to operators
discretion. Full details of the procedure were collected including use
of resources, devices, radiation, contrast and myocardial enzymes and
creatinine before and after procedure.
RESULTS A total of 100 patients (124 lesions) were included with no
signiﬁcant differences in baseline characteristics and only a trend to
have more lesions treated in the Synergy group. Pre-dilatation was
more frequent with BVS (97% vs. 24%;p<0.001). Implanted stents had
similar diameter (30.4 mm in BVS and 30.5 mm in Synergy) and
length (196 mm in BVS and 208 mm in Synergy). Post-dilatation
was more frequently done with BVS (58% vs. 42%:p¼0.1) using very
similar balloons (3.3 mm diameter in both groups) and peak pressure
(16 atm and 15 atm respectively). The number of wires and catheters
was equivalent. The BVS group showed an increase in use of contrast
volume of 10%, increase in radiation of 28% and an increase in the 24
h post-PCI TnI value a 53% higher in comparison with the Synergy
group. No cases of contrast-induced nephropathy were noted.
CONCLUSIONS The use of current generation of BVS in comparison
with the Synergy stent in a similar lesional setting is associated with
a higher use of resources in the procedure, more radiation and a to
higher TnI release after PCI.
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BACKGROUND In the ASSURE registry, the treatment of de-novo
coronary artery lesions in a real world setting with everolimus-eluting
bioresorbable scaffolds (Absorb, Abbott Vascular, Santa Clara, CA,
USA) was associated with favorable clinical 1-year outcomes. The
current investigation aimed to assess efﬁcacy and safety over a longer
period of time. Here we report on clinical outcomes and angiographic
ﬁndings at 2 years.
METHODS In the prospective, multicenter registry, 183 consecutive
patients received bioresorbable scaffolds at 6 German sites. Two-year
outcomes of equal weight were angina status and freedom from major
adverse cardiovascular events (MACE) and target vessel failure or
revascularization. Quantitative angiography was conducted at follow-
up and in the event of ischemia driven revascularization.
RESULTS Two-year clinical follow-up was completed in 170 (92.9%)
patients. Three (1.8%) patients died for cardiovascular reasons, one
from gastrointestinal bleeding, one from sudden cardiac death, and
one from cardiorespiratory insufﬁciency. Five (2.9%) myocardial in-
farctions due to non-target lesions occurred, and 9 (5.3%) ischemia
driven target lesion revascularizations had become necessary because
of in-scaffold restenosis. One of the participating centers with a 82.1%
(46/56 patients) angiographic follow-up reported on a 20.4% (10/49)
rate of  70% diameter restenosis through 2 years, half of which
associated with symptoms of ischemia. No scaffold thrombosis was
observed. Freedom from MACE was 91.6%  2.1% (95% CI [87.4% -
95,8%]). Ten patients (5.9%) experienced a target vessel failure or
revascularization. Clinical improvement was sustained over two
years, with no substantial change in the rate of angina pectoris since
the 6- and 12-month follow up (16.8% versus 16.9% and 17.3%,
respectively). Quantitative angiographic core lab results from 71 pa-
tients (38.8%) will be available by August 2015.
CONCLUSIONS Two-year ASSURE results suggest that bioresorbable
scaffolds for de-novo coronary artery lesions in daily clinical practice
are safe and effective in the mid term. No scaffold thrombosis was
observed. A considerable number of asymptomatic in-scaffoldrestenoses may have remained undetected. (ClinicalTrials.gov:
NCT01583608)
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BACKGROUND This study sought to investigate the edge vascular
response (EVR) after implantation of an everolimus-eluting bio-
resorbable Absorb scaffold using serial optical coherence tomography
(OCT) imaging.
METHODS In the ﬁrst-in-man ABSORB Cohort B trial, 28 patients with
29 lesions underwent truly serial OCT examinations at 4 different time
points (Cohort B1: post-procedure, 6 months, 24 months, and 60
months [n¼13]; B2: post-procedure, 12 months, 36 months, and 60
months [n¼15]) after implantation of an 3.0-mm x 18-mm Absorb
scaffold. A frame-by-frame (200 mm) OCT analysis was performed at
the 5-mm proximal edge, 5-mm distal edge, and 2-mm in-scaffold
margin, whereas the middle 14-mm in-scaffold segment was analyzed
at 1-mm intervals.
RESULTS There was no signiﬁcant change in the lumen area at the
distal edge segment through the entire follow-up period, although
at the distal edge segment the lumen area tended to increase be-
tween post-procedure and 6 months (Cohort B1: 4.94  1.23 mm2
for post-procedure; 5.39  1.83 mm2 for 6 months [p¼0.0520, for
post-procedure vs. 6 months]; 4.95  1.26 mm2 for 24 months; 5.61
 2.08 mm2 for 60 months). In contrast, there was a signiﬁcant
reduction of the lumen in the 2-mm distal margin of the scaffold
between post-procedure and 12 months (at the 1-mm margin: 7.31 
1.02 mm2 vs. 5.66  1.26 mm2, and 2-mm margin: 7.36  1.04 mm2
vs. 5.64  1.30 mm2, respectively, p¼0.001). There was no signiﬁ-
cant change of the lumen in the 2-mm distal margin of the scaffold
between 12 months and 60 months (at the 1-mm margin: 5.66 
1.26 mm2 vs. 4.89  2.02 mm2 [p¼0.116], and 2-mm margin: 5.64 
1.30 mm2 vs. 5.18  1.96 mm2 [p¼0.211]). At the proximal edge
segment the lumen area decreased signiﬁcantly between post-pro-
cedure and 12 months (Cohort B2: 7.20  1.75 mm2 vs. 6.70 
1.53 mm2 p¼0.0168), however between 12 months and 60 months
the lumen remained stable (6.70  1.53 mm2 vs. 6.22  1.83 mm2
p¼0.4623). The 2-mm proximal margin of scaffold segment also
showed a similar change; a signiﬁcant reduction of lumen area at
the ﬁrst 1-mm edge between post-procedure and 12 months (7.49 
1.45 mm2 vs. 6.55  1.08mm2, p¼0.019), however there was no
signiﬁcant change of lumen area at the ﬁrst 1-mm edge between 12
months and 60 months (6.55  1.08 mm2 vs. 5.81  1.22 mm2,
p¼0.508). In the Cohort with 6 months, 24 months, and 60 months
follow-up, no signiﬁcant change was observed in the lumen of the
proximal edge segment (6.37  3.18 mm2 for post-procedure, 6.63 
2.68 mm2 for 6 months, 6.73  2.70 mm2 for 24 months, 6.69 
2.61 mm2 for 60 months).
CONCLUSIONS In the limited number of serial observations by OCT,
some degree of lumen reduction was observed in the proximal edge in
the ﬁrst year after implantation of an Absorb scaffold. However, after
one year the lumen at the both proximal and distal edges remained
stable. The edge effect seems to be a temporary phenomenon,
observed only in the ﬁrst year after implantation.
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